HLS Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
HLS Therapeutics has a total shareholder equity of $79.3M and total debt of $67.8M, which brings its debt-to-equity ratio to 85.4%. Its total assets and total liabilities are $171.7M and $92.4M respectively.
Key information
85.4%
Debt to equity ratio
US$67.78m
Debt
| Interest coverage ratio | n/a |
| Cash | US$17.54m |
| Equity | US$79.33m |
| Total liabilities | US$92.41m |
| Total assets | US$171.74m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 74D's short term assets ($37.6M) exceed its short term liabilities ($24.1M).
Long Term Liabilities: 74D's short term assets ($37.6M) do not cover its long term liabilities ($68.3M).
Debt to Equity History and Analysis
Debt Level: 74D's net debt to equity ratio (63.3%) is considered high.
Reducing Debt: 74D's debt to equity ratio has increased from 50.7% to 85.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 74D has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 74D is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 6.2% per year.